Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.06
Percentage change -3.37	%

Peers: LH DGX MYGN EXAS MEDP CMRX VNDA BCRX TECH CRL

| Held by: IWM VTI VB VXF IWN VBR IBB VBK SCHA PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.09	Insider Own	54.79%	Shs Outstand	671.55M	Perf Week	-8.99%
Market Cap	1.16B	Forward P/E	-	EPS next Y	-0.26	Insider Trans	0.57%	Shs Float	303.61M	Perf Month	6.17%
Income	-53.25M	PEG	-	EPS next Q	-0.08	Inst Own	31.40%	Short Float	29.47%	Perf Quarter	8.86%
Sales	713.10M	P/S	1.62	EPS this Y	-297.92%	Inst Trans	6.78%	Short Ratio	18.44	Perf Half Y	8.18%
Book/sh	2.03	P/B	0.85	EPS next Y	19.58%	ROA	-2.53%	Short Interest	89.47M	Perf Year	82.61%
Cash/sh	0.64	P/C	2.67	EPS next 5Y	-11.20%	ROE	-3.87%	52W Range	0.86 - 2.04	Perf YTD	17.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.04%	ROI	-2.89%	52W High	-15.48%	Beta	1.74
Dividend TTM	-	Quick Ratio	3.13	Sales past 5Y	1.59%	Gross Margin	19.05%	52W Low	99.98%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	3.43	EPS Y/Y TTM	70.55%	Oper. Margin	-38.36%	RSI (14)	49.72	Volatility	5.43% 5.12%
Employees	2997	Debt/Eq	0.37	Sales Y/Y TTM	-17.42%	Profit Margin	-7.47%	Recom	1.00	Target Price	3.99
Option/Short	Yes / Yes	LT Debt/Eq	0.35	EPS Q/Q	116.61%	Payout	-	Rel Volume	0.53	Prev Close	1.78
Sales Surprise	18.13%	EPS Surprise	110.72%	Sales Q/Q	0.93%	Earnings	Feb 27 AMC	Avg Volume	4.85M	Price	1.72
SMA20	-1.74%	SMA50	6.89%	SMA200	13.95%	Trades		Volume	2,558,223	Change	-3.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy	$10 → $14.50
May-30-13	Reiterated	Ladenburg Thalmann	Buy	$8.50 → $10
Oct-22-12	Initiated	Barrington Research	Outperform	$6
Dec-01-11	Reiterated	Ladenburg Thalmann	Buy	$6 → $8.50
Jul-14-11	Initiated	Ladenburg Thalmann	Buy	$6

Show Previous Ratings

Mar-12-25 12:10PM	Labcorp to acquire certain assets of Opko Healths BioReference Health (TipRanks)
11:06AM	Truist remains bullish on Labcorp after another nice strategic acquisition (TipRanks)
Mar-11-25 07:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Feb-28-25 09:01AM	Q4 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.75%
02:35AM	OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)
10:45PM	Loading…
Feb-27-25 10:45PM	Opko Health (OPK) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00PM	OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates (Zacks)
05:58PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:10PM	OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Feb-25-25 09:15AM	Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-13-25 04:05PM	OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-12-25 09:15AM	Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-20-25 10:02PM	OPKO Health, Inc. (OPK) Stock: An Under $5 Gem with Biggest Upside Potential (Insider Monkey)
11:45AM	Loading…
Jan-09-25 11:45AM	OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck (GlobeNewswire)
Dec-11-24 02:08AM	Is OPKO Health (OPK) the Best NASDAQ Penny Stock to Buy Right Now? (Insider Monkey)
Dec-10-24 08:00AM	NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer (PR Newswire)
Nov-29-24 02:43PM	Sleep Number, Getty Images, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-20-24 08:00AM	OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo (PR Newswire)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-14-24 06:00AM	NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results (PR Newswire)
Nov-08-24 04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
04:01AM	OPKO Health Inc (OPK) Q3 2024 Earnings Call Highlights: A Turnaround in Profitability Amidst ... (GuruFocus.com)
Nov-07-24 10:15PM	Opko Health (OPK) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings (Zacks)
06:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
05:35PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference to Include OvaWatch (GlobeNewswire)
Oct-29-24 04:05PM	OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire) +6.67% -5.00%
Oct-07-24 08:00AM	NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan (PR Newswire)
08:00AM	ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-23-24 08:00AM	OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development (GlobeNewswire)
Sep-16-24 07:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health (PR Newswire)
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-08-24 12:14PM	OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down (Zacks) +11.72%
12:15AM	Opko Health (OPK) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-07-24 08:00PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:59PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:06PM	OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-01-24 04:05PM	OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	OPKO Health Announces $100 Million Share Repurchase Program (GlobeNewswire) +7.04%
Jul-17-24 04:14PM	OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments (GlobeNewswire)
Jul-08-24 06:54PM	OPKO Health, Inc. (OPK): Most Shorted Stock Loved by Analysts Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner (PR Newswire)
Jun-06-24 11:31AM	Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? (Zacks)
May-31-24 10:48AM	OPKO Health to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
10:00AM	The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now (InvestorPlace)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 09:18AM	OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y (Zacks)
May-08-24 11:47AM	OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:56AM	Q1 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:44AM	OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ... (GuruFocus.com)
May-07-24 09:15PM	Opko Health (OPK) Q1 2024 Earnings Call Transcript (Motley Fool)
08:30PM	OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:09PM	OPKO Health Inc (OPK) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
05:30PM	OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:38PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-03-24 08:00AM	OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-01-24 01:01PM	OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp (Zacks) +9.17%
Mar-28-24 11:08PM	Labcorp inks $237.5M buyout of Opkos reproductive, womens health testing assets (MedTech Dive) +12.15%
08:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business (PR Newswire)
Mar-25-24 09:57AM	OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 (Zacks)
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire)
Mar-05-24 08:52AM	AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV (GlobeNewswire) -6.51%
Feb-29-24 08:31AM	OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 09:31AM	NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st (PR Newswire) -6.14%
09:02AM	OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top (Zacks)
06:18AM	Q4 2023 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 09:00PM	Opko Health (OPK) Q4 2023 Earnings Call Transcript (Motley Fool) +5.37%
07:30PM	OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:08PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:43PM	OPKO Health Inc (OPK) Reports Fourth Quarter 2023 Results (GuruFocus.com)
04:05PM	OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Feb-26-24 09:16AM	Gear Up for OPKO Health (OPK) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks) +5.34%
Feb-22-24 04:05PM	OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-08-24 01:48PM	Hedge Fund and Insider Trading News: Adam Schwartz, Bill Ackman, Eisler Capital, Brevan Howard Asset Management, Balyasny Asset Management, Citadel LLC, OPKO Health, Inc. (OPK), and More (Insider Monkey)
Feb-05-24 08:09AM	NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China (PR Newswire)
Jan-22-24 11:48AM	3 Stocks with Major Insider Buying This Month (InvestorPlace)
Jan-09-24 04:05PM	OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes (GlobeNewswire)
Jan-08-24 08:00AM	OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.54%
Jan-04-24 11:31PM	OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029 (GlobeNewswire) -39.55%
Jan-03-24 05:05PM	OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029 (GlobeNewswire)
Dec-07-23 10:20AM	Here's Why You Should Retain OPKO Health (OPK) Stock for Now (Zacks)
Dec-06-23 11:30AM	Why Is OPKO Health (OPK) Up 18.7% Since Last Earnings Report? (Zacks)
Nov-28-23 07:00AM	BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing (PR Newswire)
Nov-07-23 10:36AM	Q3 2023 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
10:29AM	OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top (Zacks)
09:19AM	OPKO Health, Inc. (NASDAQ:OPK) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:45AM	BioReference Signs On as the First Laboratory to Use MSK-ACCESS Powered with SOPHiA DDM (PR Newswire)
01:00AM	Opko Health (OPK) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-06-23 07:30PM	OPKO Health (OPK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:30PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 28 '25	Buy	1.71	67,434	115,312	213,301,448	Feb 28 07:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 28 '25	Buy	1.47	47,537	70,060	213,234,014	Jan 28 05:40 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 17 '25	Buy	1.47	150,000	220,425	213,186,477	Jan 17 05:06 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 15 '25	Buy	1.48	500,000	740,850	213,036,477	Jan 15 05:18 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 13 '24	Buy	1.59	125,000	199,375	212,536,477	Dec 13 05:04 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 11 '24	Buy	1.56	500,000	781,050	212,411,477	Dec 11 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 29 '24	Buy	1.53	199,072	305,376	211,911,477	Nov 29 03:20 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 22 '24	Buy	1.59	100,000	159,000	211,712,405	Nov 22 05:17 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 14 '24	Buy	1.62	100,000	161,980	211,612,405	Nov 14 05:51 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 08 '24	Buy	1.50	280,183	421,535	211,512,405	Nov 08 05:40 PM
OPKO HEALTH, INC.	10% Owner	Sep 17 '24	Proposed Sale	40.88	13,404	547,956		Sep 20 02:56 PM
OPKO HEALTH, INC.	10% Owner	Aug 19 '24	Sale	34.49	50,000	1,724,520	2,646,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 16 '24	Sale	34.30	50,000	1,714,850	2,696,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 15 '24	Sale	33.08	39,824	1,317,505	2,746,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 12 '24	Sale	33.95	59,787	2,029,811	2,811,783	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 13 '24	Sale	34.76	24,987	868,503	2,786,796	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 08 '24	Sale	31.82	100,000	3,182,380	2,871,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Aug 06 '24	Sale	29.35	12,994	381,427	2,971,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 31 '24	Sale	33.50	88,839	2,976,346	2,984,564	Aug 02 04:21 PM
OPKO HEALTH, INC.	10% Owner	Jul 29 '24	Sale	33.86	50,000	1,692,890	3,073,403	Jul 31 05:03 PM
OPKO HEALTH, INC.	10% Owner	Jul 24 '24	Sale	33.72	75,000	2,529,105	3,183,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 26 '24	Sale	33.85	60,000	2,031,258	3,123,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 23 '24	Sale	33.46	75,000	2,509,245	3,258,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 22 '24	Sale	32.61	50,000	1,630,440	3,333,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 19 '24	Sale	32.29	25,000	807,250	3,383,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 17 '24	Sale	32.93	25,000	823,188	3,408,403	Jul 19 06:46 PM
OPKO HEALTH, INC.	10% Owner	Jul 05 '24	Sale	28.24	36,118	1,020,016	3,433,403	Jul 09 04:07 PM
OPKO HEALTH, INC.	10% Owner	Jul 01 '24	Sale	26.63	50,000	1,331,700	3,508,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 02 '24	Sale	29.12	25,000	728,095	3,483,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 03 '24	Sale	28.23	14,082	397,491	3,469,521	Jul 03 04:56 PM
FROST PHILLIP MD ET AL	CEO & Chairman	May 23 '24	Buy	1.27	100,000	126,937	211,232,222	May 23 08:04 PM
FROST PHILLIP MD ET AL	CEO & Chairman	May 17 '24	Buy	1.29	163,997	211,195	211,132,222	May 17 05:31 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 18 '24	Buy	0.87	500,000	437,100	210,968,225	Mar 18 04:45 PM

Open in Screener

BCDA

BioCardia Inc

Mar 13 • 04:00PM ET

2.57

Dollar change +0.02
Percentage change 0.78	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-4.16	Insider Own	21.01%	Shs Outstand	4.52M	Perf Week	-0.39%
Market Cap	11.78M	Forward P/E	-	EPS next Y	-1.31	Insider Trans	4.39%	Shs Float	3.62M	Perf Month	2.39%
Income	-7.72M	PEG	-	EPS next Q	-0.62	Inst Own	2.72%	Short Float	0.65%	Perf Quarter	10.30%
Sales	0.07M	P/S	168.29	EPS this Y	62.30%	Inst Trans	27.04%	Short Ratio	0.44	Perf Half Y	0.00%
Book/sh	0.61	P/B	4.22	EPS next Y	57.88%	ROA	-154.22%	Short Interest	0.02M	Perf Year	-59.35%
Cash/sh	1.08	P/C	2.39	EPS next 5Y	44.44%	ROE	-737.89%	52W Range	1.62 - 6.41	Perf YTD	17.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.13%	ROI	-225.33%	52W High	-59.88%	Beta	1.15
Dividend TTM	-	Quick Ratio	1.78	Sales past 5Y	122.23%	Gross Margin	-498.59%	52W Low	58.15%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	1.78	EPS Y/Y TTM	55.71%	Oper. Margin	-10935.21%	RSI (14)	56.03	Volatility	6.48% 10.16%
Employees	20	Debt/Eq	0.38	Sales Y/Y TTM	-87.54%	Profit Margin	-10876.06%	Recom	1.00	Target Price	15.50
Option/Short	No / Yes	LT Debt/Eq	0.24	EPS Q/Q	65.61%	Payout	-	Rel Volume	0.44	Prev Close	2.55
Sales Surprise	-100.00%	EPS Surprise	48.74%	Sales Q/Q	-100.00%	Earnings	Nov 13 AMC	Avg Volume	53.28K	Price	2.57
SMA20	5.07%	SMA50	8.91%	SMA200	-4.84%	Trades		Volume	23,147	Change	0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
07:00AM	Loading…
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
08:30AM	Loading…
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
07:00AM	Loading…
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-01-23 05:04PM	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023 (GlobeNewswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks) -13.88%
Oct-11-23 06:00AM	BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II (GlobeNewswire) +28.30%
Sep-06-23 10:31AM	BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study (Zacks) -12.59%
07:15AM	BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs (GlobeNewswire)
Sep-05-23 07:15AM	BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire) -25.54%
Aug-11-23 09:29AM	BioCardia, Inc. (NASDAQ:BCDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-09-23 06:05PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.28%
04:05PM	BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Aug-02-23 07:00AM	BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 (GlobeNewswire)
Jul-24-23 07:00AM	BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected (GlobeNewswire) -44.70%
Jul-10-23 08:11AM	Those who invested in BioCardia (NASDAQ:BCDA) a year ago are up 86% (Simply Wall St.)
Jul-05-23 07:00AM	BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japans Pharmaceutical Medical Device Agency (GlobeNewswire)
Jun-20-23 05:14PM	BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire) +6.41% +12.45%
Jun-08-23 07:00AM	BioCardia Announces Helix Biotherapeutic Delivery Patent Issuance in Japan (GlobeNewswire) +6.53%
May-28-23 08:08AM	Joseph Daly Spends US$177k Buying BioCardia Shares \ (Simply Wall St.)
May-23-23 07:00AM	BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire)
May-12-23 06:06AM	BioCardia First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-10-23 05:45PM	BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	BioCardia Reports First Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
May-09-23 07:00AM	BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications (GlobeNewswire)
May-03-23 08:00PM	BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023 (GlobeNewswire)
Apr-28-23 07:00AM	BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available (GlobeNewswire)
Apr-04-23 07:00AM	BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies (GlobeNewswire)
Apr-01-23 12:47PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:05AM	We're Keeping An Eye On BioCardia's (NASDAQ:BCDA) Cash Burn Rate (Simply Wall St.)
Mar-29-23 08:15AM	BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results (GlobeNewswire)
Mar-16-23 07:00AM	BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023 (GlobeNewswire)
Mar-06-23 01:06PM	BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study (Benzinga)
07:00AM	Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting (GlobeNewswire)
Feb-01-23 06:30AM	BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients (GlobeNewswire) -7.48%
Jan-31-23 05:39AM	Shareholders in BioCardia (NASDAQ:BCDA) are in the red if they invested five years ago (Simply Wall St.)
Dec-22-22 07:00AM	BioCardia Letter to Shareholders (GlobeNewswire)
Dec-21-22 05:07AM	Insider Buying: The BioCardia, Inc. (NASDAQ:BCDA) Independent Director Just Bought 14% More Shares (Simply Wall St.) +6.55%
Dec-15-22 07:00AM	BioCardia Announces $3.6 Million Private Placement of Common Stock (GlobeNewswire)
Dec-06-22 07:00AM	BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure (Business Wire)
Nov-09-22 05:35PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results (GlobeNewswire)
12:00PM	BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-02-22 05:31PM	BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022 (GlobeNewswire)
Oct-03-22 01:33PM	BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years (Benzinga) +5.67%
07:00AM	BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting (GlobeNewswire)
Sep-14-22 07:00AM	CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STERTZER SIMON H	Director	Mar 05 '25	Buy	2.45	1,000	2,450	57,138	Mar 07 08:30 AM
STERTZER SIMON H	Director	Mar 03 '25	Buy	2.30	22,753	52,332	40,602	Mar 05 08:30 AM
STERTZER SIMON H	Director	Mar 04 '25	Buy	2.30	15,536	35,733	56,138	Mar 05 08:30 AM
Altman Peter	President and CEO	Mar 03 '25	Buy	2.11	500	1,055	108,420	Mar 04 08:30 AM
Altman Peter	President and CEO	Feb 07 '25	Buy	2.48	600	1,488	107,920	Feb 11 05:42 PM
Altman Peter	President and CEO	Jan 29 '25	Buy	2.40	500	1,200	107,081	Jan 30 08:36 PM
Altman Peter	President and CEO	Jan 30 '25	Buy	2.38	239	569	107,320	Jan 30 08:36 PM
Altman Peter	President and CEO	Dec 23 '24	Buy	2.06	1,000	2,060	106,581	Dec 26 02:30 PM
GILLIS EDWARD M	Senior Vice President, Devices	Dec 20 '24	Sale	2.00	3,257	6,514	8,968	Dec 26 02:30 PM
GILLIS EDWARD M	Officer	Dec 17 '24	Proposed Sale	2.03	3,257	6,611		Dec 17 11:50 AM
Altman Peter	President and CEO	Dec 05 '24	Buy	2.22	250	555	105,581	Dec 09 05:04 PM
Altman Peter	President and CEO	Nov 15 '24	Buy	1.87	1,350	2,524	105,331	Nov 19 08:00 AM
Altman Peter	President and CEO	Jul 01 '24	Buy	3.05	300	915	39,745	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 28 '24	Buy	2.99	200	598	39,445	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 21 '24	Buy	3.29	500	1,645	39,245	Jun 24 08:46 AM
Altman Peter	President and CEO	Jun 14 '24	Buy	3.52	500	1,760	38,745	Jun 17 07:00 AM
Altman Peter	President and CEO	Jun 10 '24	Buy	3.36	1,000	3,360	38,245	Jun 12 07:00 AM
Altman Peter	President and CEO	Apr 19 '24	Buy	0.37	2,750	1,013	558,697	Apr 19 05:38 PM
Altman Peter	President and CEO	Mar 28 '24	Buy	0.39	500	195	555,947	Mar 28 07:33 PM

Dollar change -0.44
Percentage change -17.67	%

Peers: TTD MGNI ZS APPS PERI APP CRTO PUBM DV ACMR

| Held by: VTI VXF BSVO IWC DFSU DFAC DFAT

Index	-	P/E	-	EPS (ttm)	-1.87	Insider Own	54.23%	Shs Outstand	20.02M	Perf Week	-20.54%
Market Cap	39.69M	Forward P/E	31.54	EPS next Y	0.07	Insider Trans	-0.01%	Shs Float	8.86M	Perf Month	-31.09%
Income	-29.28M	PEG	-	EPS next Q	-0.29	Inst Own	34.38%	Short Float	0.33%	Perf Quarter	-28.07%
Sales	254.62M	P/S	0.16	EPS this Y	59.21%	Inst Trans	22.26%	Short Ratio	2.00	Perf Half Y	-25.45%
Book/sh	1.25	P/B	1.64	EPS next Y	113.98%	ROA	-28.50%	Short Interest	0.03M	Perf Year	-38.55%
Cash/sh	0.55	P/C	3.71	EPS next 5Y	-	ROE	-98.64%	52W Range	2.31 - 4.30	Perf YTD	-18.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-68.62%	ROI	-101.19%	52W High	-52.32%	Beta	2.15
Dividend TTM	-	Quick Ratio	0.94	Sales past 5Y	-1.22%	Gross Margin	19.98%	52W Low	-11.24%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	1.02	EPS Y/Y TTM	59.39%	Oper. Margin	-7.21%	RSI (14)	27.39	Volatility	10.06% 6.53%
Employees	277	Debt/Eq	1.50	Sales Y/Y TTM	-14.67%	Profit Margin	-11.50%	Recom	3.00	Target Price	3.50
Option/Short	No / Yes	LT Debt/Eq	0.16	EPS Q/Q	-36.13%	Payout	-	Rel Volume	4.14	Prev Close	2.49
Sales Surprise	-3.88%	EPS Surprise	21.74%	Sales Q/Q	-10.11%	Earnings	Feb 28 BMO	Avg Volume	14.64K	Price	2.05
SMA20	-23.46%	SMA50	-25.60%	SMA200	-32.11%	Trades		Volume	57,836	Change	-17.67%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-22	Upgrade	Barrington Research	Mkt Perform → Outperform	$2.50
Mar-17-21	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-02-20	Upgrade	Barrington Research	Mkt Perform → Outperform	$4.50
Aug-26-20	Initiated	Canaccord Genuity	Buy	$5
Nov-12-19	Downgrade	Barrington Research	Outperform → Mkt Perform
May-09-19	Upgrade	ROTH Capital	Neutral → Buy	$5.50 → $8.50

Mar-01-25 02:58AM	Q4 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	Fluent Inc (FLNT) Q4 2024 Earnings Call Highlights: Navigating Challenges with Commerce Media Growth (GuruFocus.com)
Feb-28-25 09:10AM	Fluent (FLNT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Fluent Announces Unaudited Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 08:00PM	Fluent, Inc. to Announce Unaudited 2024 Fourth Quarter and Full-Year Financial Results and Host Earnings Conference Call on February 28, 2025 (GlobeNewswire) +5.49%
08:30AM	Loading…
Feb-19-25 08:30AM	Fluent, Inc. Appoints Adrian Stack as Chief Product Officer; Accelerates AI-Powered Innovation in Commerce Media (GlobeNewswire)
Feb-05-25 08:30AM	Fluent, Inc. Survey Finds That Shoppers Embrace Post-Purchase Ads, Citing Personalization & Relevance as Key Benefits (GlobeNewswire)
Jan-27-25 12:00PM	Fluent, Inc. Named to Ad Age's 2025 Best Places to Work List (GlobeNewswire)
Jan-17-25 03:34PM	Global Value Investment Corporation's Interim CEO and President JP Geygan Appointed to Fluent, Inc.'s Board of Directors (GlobeNewswire)
Jan-07-25 08:30AM	Fluent, Inc. Announces Commerce Media Partnerships with Top-Tier Brands (GlobeNewswire) +6.04%
Dec-06-24 03:17PM	Why Is Fluent, Inc. (FLNT) Among The Best Advertising Stocks to Buy According to Hedge Funds? (Insider Monkey) +5.75%
Nov-29-24 05:58PM	Fluent, Inc. Announces $5.75 Million Registered Direct Offering and $2.75 Million Concurrent Private Offering (GlobeNewswire)
Nov-19-24 04:00PM	Fluent, Inc. Files New Investor Presentation and Makes Available on Company Website (GlobeNewswire) -5.32%
Nov-15-24 01:04PM	Q3 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -6.62%
02:15AM	Fluent Inc (FLNT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... (GuruFocus.com)
05:12PM	Loading…
Nov-14-24 05:12PM	Fluent: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces Third Quarter 2024 Financial Results; Strategic Pivot Accelerates with Growth of Commerce Media Solutions (GlobeNewswire)
Nov-13-24 02:30PM	Fluent, Inc. to Announce 2024 Third Quarter Financial Results on November 14, 2024 (GlobeNewswire) -5.33%
Sep-10-24 10:00AM	Ryan Perfit Appointed Chief Financial Officer of Fluent, Inc. (GlobeNewswire)
Sep-06-24 08:30AM	Fluent, Inc. to Participate in the 17th Annual Barrington Research Virtual Fall Investment Conference (GlobeNewswire)
Aug-22-24 09:40AM	Are Investors Undervaluing Fluent (FLNT) Right Now? (Zacks)
Aug-20-24 08:11AM	Q2 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -9.67%
Aug-19-24 05:10PM	Fluent (FLNT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Fluent Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-15-24 10:00AM	Fluent, Inc. to Announce 2024 Second Quarter Financial Results on August 19, 2024 (GlobeNewswire)
Jul-12-24 08:30AM	Fluent, Inc. Announces Strategic Partnership with US Retailer, Hy-Vee, and Its Retail Media Network, RedMedia, to Enhance Customer Experience (GlobeNewswire)
Jun-28-24 08:30AM	Fluent, Inc. Announces Inclusion in Russell Microcap Index (GlobeNewswire) +7.76%
May-28-24 09:40AM	Is Fluent (FLNT) Stock Undervalued Right Now? (Zacks)
May-16-24 11:39AM	Q1 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -13.10%
08:16AM	Fluent, Inc. (NASDAQ:FLNT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:34AM	Loading…
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
03:07AM	Fluent Inc (FLNT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts Amid Revenue ... (GuruFocus.com)
May-15-24 08:52PM	FLNT Stock Earnings: Fluent Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:45PM	Fluent: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 01:19PM	Fluent, Inc. to Announce 2024 First Quarter Financial Results on May 15, 2024 (GlobeNewswire)
May-02-24 07:00AM	SLR Credit Solutions Agents Senior Credit Facility for Fluent, Inc. (Business Wire)
Apr-10-24 08:00AM	Fluent Announces Reverse Stock Split (GlobeNewswire)
Apr-03-24 09:00AM	Influencer Media Group Infuse Follows Up on Stellar 2023 Growth with New Partnership, Podcast Launch, and Influencer Events (GlobeNewswire)
06:44AM	Q4 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-02-24 05:32PM	Fluent Announces Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 10:48PM	Fluent, Inc. to Announce Fourth Quarter and Full-Year 2023 Financial Results on April 2, 2024 (GlobeNewswire)
Mar-21-24 09:00AM	Fluent Partners with Fyllo Semasio to Expand Audience Solutions with Contextual Offering (GlobeNewswire)
Feb-29-24 02:25PM	Fluent (FLNT) Reports Break-Even Earnings for Q4 (Zacks) +9.44%
12:22PM	Fluent Announces Expected Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 09:00AM	New Fluent Survey of Retailers and Brands Measures Commerce Media Strategies and Challenges (GlobeNewswire) -5.51%
Jan-25-24 08:30AM	Fluent Secures Top Spot as the #1 Digital Agency in Ad Age's 2024 Best Places to Work List (GlobeNewswire)
Nov-15-23 09:55AM	Q3 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -16.50%
Nov-14-23 05:11PM	UPDATE - Fluent Announces Third Quarter 2023 Financial Results (GlobeNewswire) +6.64%
04:54PM	Fluent: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 03:00PM	Fluent, Inc. to Announce Third Quarter Financial Results on November 14, 2023 (GlobeNewswire) +5.55%
Aug-22-23 08:30AM	Fluent, Inc. Launches Infuse Influencer Platform to Unlock New Customer Acquisition Opportunities for Advertisers (GlobeNewswire)
Aug-15-23 12:04PM	Fluent, Inc. (NASDAQ:FLNT) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:05AM	Q2 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:30PM	Fluent Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 09:09PM	7 Stocks That Could Triple Your Money by 2024 (InvestorPlace)
Aug-08-23 08:30AM	Fluent Launches Post-Transaction Ecommerce Advertising Solution (GlobeNewswire)
Aug-02-23 08:30AM	AdParlor Introduces CreatorFuel: A Full-Funnel Influencer Marketing Solution (GlobeNewswire)
Aug-01-23 03:30PM	Fluent, Inc. to Announce Second Quarter Financial Results on August 14, 2023 (GlobeNewswire)
Jul-27-23 08:30AM	Fluent, Inc.'s 2023 Mobile Gaming Survey Reveals Generational Insights into Gamers' Behavior and Preferences (GlobeNewswire)
Jul-10-23 10:14AM	Several Insiders Invested In Fluent Flagging Positive News (Simply Wall St.)
Jun-13-23 08:42AM	Investors in Fluent (NASDAQ:FLNT) have unfortunately lost 77% over the last five years (Simply Wall St.)
May-17-23 06:15AM	Investors Will Want Fluent's (NASDAQ:FLNT) Growth In ROCE To Persist (Simply Wall St.)
May-16-23 08:01AM	Q1 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -20.19%
May-15-23 04:15PM	Fluent Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-12-23 02:10PM	Fluent (FLNT) to Post Q1 Earnings: What's in the Offing? (Zacks)
May-11-23 09:40AM	Should Value Investors Buy Fluent (FLNT) Stock? (Zacks)
May-02-23 05:50PM	Fluent (FLNT) Stock Moves -0.67%: What You Should Know (Zacks)
08:30AM	Fluent, Inc. to Announce First Quarter Financial Results on May 15, 2023 (GlobeNewswire)
May-01-23 09:00AM	Here is What to Know Beyond Why FLUENT, INC. (FLNT) is a Trending Stock (Zacks)
Apr-26-23 05:50PM	Fluent (FLNT) Stock Moves -0.16%: What You Should Know (Zacks)
Apr-20-23 05:50PM	Fluent (FLNT) Flat As Market Sinks: What You Should Know (Zacks)
Apr-18-23 10:02AM	Investors Aren't Entirely Convinced By Fluent, Inc.'s (NASDAQ:FLNT) Revenues (Simply Wall St.)
09:00AM	Is Trending Stock FLUENT, INC. (FLNT) a Buy Now? (Zacks)
Apr-07-23 09:35AM	After Plunging -50.86% in 4 Weeks, Here's Why the Trend Might Reverse for Fluent (FLNT) (Zacks)
Apr-06-23 08:30AM	Fluent Maintains #1 Ranking for Data Accuracy in Latest Truthset Truthscore Index (GlobeNewswire) -6.63%
Apr-05-23 09:40AM	Is Fluent (FLNT) Stock Undervalued Right Now? (Zacks) -6.16%
Mar-20-23 09:40AM	Should Value Investors Buy Fluent (FLNT) Stock? (Zacks)
05:33AM	Best Value Stocks to Buy for March 20th (Zacks)
Mar-18-23 03:12AM	Fluent, Inc. (NASDAQ:FLNT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:16AM	Fluent Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) -9.43%
Mar-16-23 05:53AM	Q4 2022 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -32.63%
Mar-15-23 04:15PM	Fluent Announces Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 09:00AM	Fluent, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 (GlobeNewswire)
Feb-08-23 09:40AM	Are Investors Undervaluing Fluent (FLNT) Right Now? (Zacks)
Jan-25-23 05:50AM	A number of insiders bought Fluent, Inc. (NASDAQ:FLNT) stock last year, which is great news for shareholders (Simply Wall St.)
Jan-20-23 09:40AM	Is Fluent (FLNT) Stock Undervalued Right Now? (Zacks)
Jan-15-23 03:10PM	13 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-22-22 07:38AM	The past five years for Fluent (NASDAQ:FLNT) investors has not been profitable (Simply Wall St.)
Nov-07-22 04:01PM	Fluent Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 08:30AM	Fluent, Inc. to Announce Third Quarter Financial Results on November 7, 2022 (GlobeNewswire) +6.50%
Oct-19-22 07:53AM	Fluent, Inc. (NASDAQ:FLNT) boasts of bullish insider sentiment with 41% ownership and they have been buying lately (Simply Wall St.)
Oct-17-22 08:30AM	Fluent, Inc. Data is Now Available in TransUnion's TruAudience® Data Marketplace to Enable Enhanced Targeting Capabilities (GlobeNewswire)
Oct-11-22 08:30AM	Fluent, Inc. Appoints David A. Graff and Richard C. Pfenniger, Jr. to Board of Directors (GlobeNewswire)
Oct-05-22 08:30AM	Fluent Launches Purpose to Empower Consumer Financial Decisions (GlobeNewswire)
Sep-14-22 06:30AM	7 Kim Kardashian Stocks to Buy (InvestorPlace)
Sep-13-22 08:30AM	Fluent Ranks #1 for Data Quality and Accuracy in Q2 2022 Truthset Truthscore Index (GlobeNewswire)
Aug-18-22 06:16AM	Insider Buying: The Fluent, Inc. (NASDAQ:FLNT) Co-Founder Just Bought 1.3% More Shares (Simply Wall St.)
Aug-09-22 08:00PM	Fluent, Inc (FLNT) Q2 2022 Earnings Call Transcript (Motley Fool) -8.16% +9.63%

Fluent, Inc. engages in the provision of digital marketing services. It operates through the Fluent and All Other segments. The Fluent segment includes delivering data and performance-based marketing executions. The All Other segment represents the operation results of AdParlor, LLC, a digital advertising solution for social media buying. The company was founded by Ryan Schulke and Matthew Conlin in 2001 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patrick Donald Huntley	Chief Executive Officer	Sep 12 '24	Sale	2.67	20,250	54,068	329,063	Dec 16 04:16 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Dec 05 '24	Buy	2.69	14,337	38,554	3,056,403	Dec 06 04:30 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Dec 04 '24	Buy	2.74	5,045	13,826	3,042,066	Dec 06 04:30 PM
Patrick Donald Huntley	Chief Executive Officer	Jul 17 '24	Option Exercise	0.00	29,551	15	349,313	Jul 17 06:20 PM
Conlin Matthew	Chief Customer Officer	Jul 17 '24	Option Exercise	0.00	487,589	244	1,601,164	Jul 17 05:00 PM
Conlin Matthew	Chief Customer Officer	Jul 17 '24	Option Exercise	0.00	73,877	37	125,039	Jul 17 05:00 PM
Schulke Ryan	Chief Strategy Officer	Jul 09 '24	Option Exercise	0.00	1,743,499	872	2,941,164	Jul 11 12:40 PM
Schulke Ryan	Chief Strategy Officer	Jun 14 '24	Buy	3.42	3,000	10,246	103,027	Jun 18 04:43 PM

Open in Screener

COCP

Cocrystal Pharma Inc

Mar 13 • 04:00PM ET

1.67

Dollar change +0.03
Percentage change 2.14	%

Healthcare • Biotechnology • USA • NASD

COCP Cocrystal Pharma Inc daily Stock Chart

Peers: MRNA BNTX GILD REGN PFE JNJ VRTX AZN NVAX SNY

| Held by: VTI VXF DFAT DFSU

Index	-	P/E	-	EPS (ttm)	-1.84	Insider Own	31.67%	Shs Outstand	10.17M	Perf Week	-5.11%
Market Cap	16.99M	Forward P/E	-	EPS next Y	-2.16	Insider Trans	0.00%	Shs Float	6.95M	Perf Month	-24.77%
Income	-18.70M	PEG	-	EPS next Q	-0.53	Inst Own	6.99%	Short Float	0.23%	Perf Quarter	-14.80%
Sales	0.00M	P/S	-	EPS this Y	-3.21%	Inst Trans	-1.10%	Short Ratio	0.33	Perf Half Y	-2.29%
Book/sh	1.25	P/B	1.34	EPS next Y	-11.92%	ROA	-76.57%	Short Interest	0.02M	Perf Year	12.84%
Cash/sh	1.29	P/C	1.30	EPS next 5Y	-11.32%	ROE	-86.20%	52W Range	1.35 - 3.26	Perf YTD	-17.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.25%	ROI	-130.92%	52W High	-48.77%	Beta	2.11
Dividend TTM	-	Quick Ratio	7.32	Sales past 5Y	-42.33%	Gross Margin	-	52W Low	23.70%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	7.32	EPS Y/Y TTM	8.73%	Oper. Margin	-	RSI (14)	40.90	Volatility	7.16% 8.94%
Employees	12	Debt/Eq	0.15	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.33
Option/Short	No / Yes	LT Debt/Eq	0.12	EPS Q/Q	-18.33%	Payout	-	Rel Volume	0.44	Prev Close	1.63
Sales Surprise	-	EPS Surprise	14.04%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	48.59K	Price	1.67
SMA20	-5.77%	SMA50	-15.49%	SMA200	-17.53%	Trades		Volume	21,430	Change	2.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-20	Initiated	H.C. Wainwright	Buy	$5

Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-06-25 08:00AM	Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections (GlobeNewswire) +6.50%
Jan-02-25 06:34AM	Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial (Clinical Trials Arena) +14.85%
Dec-31-24 02:03PM	Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement (GuruFocus.com) -37.85%
08:00AM	Loading…
08:00AM	Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 (GlobeNewswire)
Nov-13-24 08:00AM	Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Oct-31-24 08:00AM	Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins (GlobeNewswire)
Sep-26-24 08:00AM	Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts (GlobeNewswire)
Aug-19-24 04:05PM	Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences (GlobeNewswire) +15.38% -9.05%
Aug-15-24 03:00PM	CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event (ACCESSWIRE)
Aug-14-24 08:00AM	Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire) -10.53%
Jul-18-24 08:00AM	Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor (GlobeNewswire)
Jun-20-24 08:00AM	New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows (GlobeNewswire)
Jun-07-24 09:55AM	Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
01:53PM	Loading…
May-13-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
May-01-24 08:00AM	Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza (GlobeNewswire)
Mar-28-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023 (InvestorPlace) -6.67%
08:00AM	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-19-24 08:00AM	Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A (GlobeNewswire)
Mar-05-24 08:30AM	Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
Jan-04-24 08:00AM	Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates (GlobeNewswire)
Dec-06-23 08:00AM	Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-29-23 08:00AM	Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Nov-27-23 08:00AM	Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 (GlobeNewswire) +17.12%
Nov-13-23 08:00AM	Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Nov-09-23 08:00AM	Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Oct-31-23 08:00AM	Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 (GlobeNewswire) +5.25%
Oct-02-23 12:14PM	COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial. (Zacks)
08:00AM	Loading…
Sep-28-23 08:00AM	Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus (GlobeNewswire)
Sep-05-23 08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -8.38%
Aug-16-23 09:11AM	COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline. (Zacks)
Aug-14-23 08:00AM	Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Aug-08-23 08:00AM	Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead (GlobeNewswire) +7.39%
May-31-23 08:00AM	Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988 (GlobeNewswire)
May-17-23 09:26AM	COCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline. (Zacks Small Cap Research) -5.88%
May-15-23 08:00AM	Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire) -5.28%
May-04-23 04:05PM	Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-24-23 08:00AM	Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors (GlobeNewswire) +6.05%
Apr-18-23 08:00AM	Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-10-23 08:30AM	Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +12.95%
Mar-31-23 10:05AM	COCP: UPDATE: Cocrystal Pharma announces full year 2022 financial results and provides drug program updates. (Zacks Small Cap Research) +5.85%
Mar-29-23 08:00AM	Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Mar-22-23 01:03PM	COCP: UPDATE: Cocrystal Pharma announced several program updates and investor events. (Zacks Small Cap Research)
08:00AM	Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023 (GlobeNewswire)
Jan-26-23 08:00AM	Cocrystal Pharma Announces Participation in Virtual Investor Events (GlobeNewswire) -6.62%
Jan-23-23 09:00AM	Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast (Newsfile)
Dec-19-22 08:00AM	Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire) -11.39%
Dec-01-22 04:05PM	Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022 (GlobeNewswire)
Nov-17-22 01:38PM	Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A (Benzinga)
08:00AM	Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-15-22 11:19AM	COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research)
Nov-14-22 08:00AM	Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Nov-02-22 08:00AM	Cocrystal Pharma to Participate in Two Investor Conferences in November (GlobeNewswire) +13.41%
Nov-01-22 04:05PM	Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza (GlobeNewswire)
Oct-26-22 08:00AM	Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharmas Oral Antiviral Candidate CC-42344 (GlobeNewswire)
Oct-19-22 08:00AM	Cocrystal Pharma to Present at the LD Micro Main Event XV (GlobeNewswire)
Oct-13-22 08:00AM	Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 (GlobeNewswire)
Oct-11-22 11:51AM	Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate (Benzinga) -9.02%
08:00AM	Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 (GlobeNewswire)
Oct-05-22 08:00AM	Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference (GlobeNewswire)
Oct-03-22 04:05PM	Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split (GlobeNewswire) -13.65%
Sep-06-22 10:05AM	Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth (Simply Wall St.)
08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-19-22 08:10AM	COCP: UPDATE: Cocrystal Pharma releases 2022 2nd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research) -6.42%
Aug-15-22 08:00AM	Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Aug-08-22 08:00AM	Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344 (GlobeNewswire)
Aug-03-22 09:00AM	Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast (Newsfile)
Jul-14-22 08:00AM	Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing (GlobeNewswire)
Jun-01-22 08:00AM	Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
May-18-22 08:00AM	Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:12AM	COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs (Zacks Small Cap Research)
May-11-22 08:00AM	Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones (GlobeNewswire) -5.02%
Apr-21-22 08:00AM	Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
Apr-19-22 08:00AM	Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference (GlobeNewswire)
Apr-14-22 08:00AM	Cocrystal Pharma to Present at the Noble Capital Markets NobleCon18 Conference (GlobeNewswire)
Apr-12-22 11:01AM	Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial (Benzinga)
08:00AM	Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral (GlobeNewswire)
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Mar-30-22 02:57PM	We're Hopeful That Cocrystal Pharma (NASDAQ:COCP) Will Use Its Cash Wisely (Simply Wall St.)
Mar-25-22 07:30AM	COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs (Zacks Small Cap Research)
Mar-23-22 04:05PM	Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones (GlobeNewswire)
Mar-22-22 08:00AM	Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-10-22 08:00AM	Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344 (GlobeNewswire)
Mar-03-22 08:00AM	Cocrystal Pharma to Participate in Upcoming Investment Conferences (GlobeNewswire)
Feb-24-22 08:10AM	COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023 (Zacks Small Cap Research)
Jan-27-22 12:22PM	Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19 (Benzinga)
08:00AM	Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program (GlobeNewswire)
Jan-11-22 07:00AM	SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range (GlobeNewswire)
Jan-10-22 04:10PM	SomaLogic Announces Appointment of Adam Taich as Chief Business Officer (GlobeNewswire)
Jan-06-22 08:00AM	Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 (GlobeNewswire)
Jan-04-22 08:00AM	Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-22-21 08:00AM	Cocrystal Pharmas COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant (GlobeNewswire)
Dec-02-21 08:00AM	Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets Channelchek Virtual Roadshow (GlobeNewswire) -9.15%
Dec-01-21 04:05PM	Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021 (GlobeNewswire) -6.42%
Nov-15-21 12:25PM	Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones (GlobeNewswire)
Nov-08-21 03:00PM	Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:00AM	Cocrystal Pharmas SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses (GlobeNewswire)

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

OPK

Opko Health Inc

BCDA

BioCardia Inc

FLNT

Fluent Inc

COCP

Cocrystal Pharma Inc

Upgrade your FINVIZ experience